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Abstract
Background—Statins have been shown to have a protective effect for venous thromboembolism 
(VTE) in the general population. This study sought to assess the association between statins and 
the risk for cancer-associated deep vein thrombosis (DVT) and pulmonary embolism (PE).
Methods—Patients with newly diagnosed cancer were followed for up to one year in a healthcare 
claims database (2010–2013). Three treatment groups included statin users, non-statin cholesterol 
lowering medication users, and an untreated group with pre-existing indications for statin therapy 
(hyperlipidemia, diabetes, or heart disease). Propensity score matched groups were compared 
using competing risks survival models for DVT and PE outcomes reporting the hazard ratios (HR) 
between the treatment groups. Sensitivity analyses assessed the influence of age and individual 
medications.
Results—The total cohort included 170,459 patients, which, after matching, were similar on 
baseline characteristics. The overall model showed a statistically significant protective effect for 
statins compared to no treatment attributed only to leukemia for DVT (HR = 0.77, 95% CI 0.61–
0.99) and colorectal cancers for PE (HR = 0.80, 95% CI 0.64–0.99) in stratified analyses. There 
were generally no differences in outcomes between statins and non-statins and no individual statin 
use showed results different from the class effect.
Conclusions—In this propensity score matched sample of patients with cancer, statins were 
shown to have a small protective effect in some cancers for DVT or PE compared to no treatment 
and little difference compared to an active control group. The lack of effect was consistent across 
statins and was also not found for any of the sensitivity analyses included.
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1. Introduction
Cancer is among the most established independent risk factors for venous thromboembolism 
(VTE) [1]. Compared to the general population, individuals with cancer are at 4 to 7 times 
the risk of developing a VTE [2–5]. Malignancy induces a pro-thrombotic state, which 
includes activation of the coagulation cascade and is further exacerbated by cancer treatment 
[6]. Additional risk factors for VTE in cancer include patient specific factors such as the site 
and stage of the tumor, older age, prior history of thrombosis, and other comorbidities [7,8]. 
Although at an already increased risk of death from cancer, VTE carries a substantial risk of 
mortality with clotting events accounting for up to 10% of all deaths in patients with cancer 
[9–11].
Several studies have shown a link between statins and reduced risk of VTE [12–23]. 
Although the class is generally indicated to reduce atherosclerotic cardiovascular disease, 
inflammation underlies the pathogenesis of both disorders, and the anti-inflammatory effects 
of statins have been documented [14]. A key component of this process is the inhibition of 
isoprenoid synthesis, which impairs prenylation events. Although the anti-inflammatory 
properties seem to be independent from the lipid lowing properties, the effects differ among 
tissues [24]. It has further been shown that statins have antithrombotic properties and 
influence the vascular system in other ways [25]. The Heart and Estrogen/Progestin 
Replacement Study (HERS) and the JUPITER trial showed roughly a 50% decrease in the 
risk of VTE in the general population [17,26]. This finding has been substantiated in meta-
analyses, but shows a small risk reduction (10–20%) in the largest of these studies [15]. 
Tagalakis and colleagues evaluated statin use and recurrent VTE risk in a cohort ≥65 years 
of age with cancer and found a reduction in VTE risk associated with current statin use with 
further reduction with longer duration of treatment [27]. Similarly, a case-control study 
conducted in patients with cancer found the risk of cancer-associated VTE was 8% in those 
treated with statins compared to 21% in those without statin treatment [20].
The potential role and interest for statins as prophylaxis against cancer-associated VTE lies 
in the general safety of the class as well as other benefits associated with the class (e.g. 
decreased cardiovascular events). Statins pose no risk of bleeding; thus, if effective, they 
could hypothetically be used in patients who are contraindicated to anticoagulation, for long-
term prophylaxis where indefinite anticoagulation is not preferred, or as adjunct therapy in 
those already anticoagulated. However, the literature has generally shown a small overall 
benefit or has been limited by small patient populations with few outcome events to 
compare. Robust comparisons with an active control and detailed sensitivity analyses are 
also needed to strengthen the findings observed in past studies.
This study investigated the association between statin use and cancer-associated VTE in a 
U.S.-based cohort. We compared statin users with users of other non-statin cholesterol 
lowering medications as well as an untreated group, using propensity score matching 
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techniques to reduce selection bias and confounding. Sensitivity analyses included 
investigation whether certain statins provide different effects and for age as an effect 
modifier.
2. Methods
This retrospective cohort study used the Truven Health MarketScan Commercial Claims and 
Medicare Supplemental Databases from the years 2010–2013. The MarketScan data include 
approximately 40 million individuals from over 160 large employers and health plans across 
the U.S. The data represent an individual’s healthcare utilization including medical claims 
with diagnosis and procedure codes for medical encounters and all prescription medication 
fills. These data are de-identified in compliance with the Health Insurance Portability and 
Accountability Act regulations (HIPAA) and the University of Kentucky Institutional 
Review Board approved the use of the database for this study.
2.1. Cohort selection
Adults aged 18 years and older diagnosed with cancer between January 1, 2010 and 
November 31, 2013 were identified. The date of the first qualifying diagnosis of cancer was 
defined as the index date. Patients selected were diagnosed with one of the following types 
of cancer: Stomach, Pancreatic, Brain, Lung, Renal, Lymphoma, Leukemia, Myeloma, 
Colorectal, or Gynecological; identified using International Classification of Disease, 9th 
revision (ICD-9) codes. At least 2 inpatient or outpatient diagnoses separated by at least 14 
days were required to confirm the cancer diagnosis. Patients were further required to have at 
least 12 months of pre-index and a 1-month minimum of post-index continuous enrollment 
with medical and pharmacy information included in the database.
2.2. Treatment groups
Treatment groups were defined as: statin users with no history of non-statin medication use; 
non-statin cholesterol-lowering medication users with no history of statin use (“non-statin 
users,” active control group); and those with no history of statin or non-statin medication use 
(“no treatment,” control group). History of medication use was based on the 12 months of 
pre-index look back period. Current medication use for treatment group assignment was 
based on having at least 90 cumulative days supplied of the medications in the 6 months 
prior to diagnosis to establish some minimum of exposure to each medication class. Statins 
included were lovastatin, pravastatin, simvastatin, rosuvastatin, atorvastatin, fluvastatin and 
pitavastatin. Non-statins include cholesterol absorption inhibitors, fibric acid derivatives, bile 
acid sequestrants, and nicotinic acid. The no treatment group was restricted to individuals 
with a pre-index history of hyperlipidemia, coronary heart disease, or diabetes to identify a 
more comparable no treatment group with indications for statin therapy.
2.3. Study covariates
Patient demographic characteristics included age, gender, geographic region and urban 
residence. Clinical characteristics measured during the 12-month pre-index period included 
the Charlson Comorbidity Index (CCI) as a measure of comorbidity burden. Individual 
comorbidities were also included as binary variables indicating any prior diagnosis for these 
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conditions based on a list of Elixhauser comorbidities. These comorbidity indices include 17 
and 31 categories of comorbid conditions, respectively, and are widely used for risk 
adjustment with health outcomes data [28–30]. Additional pre-index medications accounted 
for included anticoagulants, antihypertensives, antiplatelets, antiarrhythmics, and digoxin, 
operationalized as binary exposures during the pre-index period.
2.4. Outcome measures
VTE outcomes included deep vein thrombosis (DVT) and pulmonary embolism (PE). Two 
separate ICD-9 coding sets were used for each outcome accounting for a broad approach and 
a more stringent definition. The broader approach included ICD-9 codes 451.xx and 453.xx 
for DVT and 415.1x for PE. The more strict definition was based on a validated ICD-9 code 
set, which includes a subgroup of these codes [31,32]. Results from the more strict definition 
of VTE events are discussed in the text while results from both definitions are provided in 
the Appendices.
2.5. Propensity score matching
Pairwise analyses were conducted between two treatment groups at a time: statins vs. non-
statins, statins vs. non-users, and non-statins vs. non-users. Propensity score matching 
mimics the randomization process of a clinical trial so that each matched pair has the same 
baseline probability to receive either treatment [33]. Propensity score matching was 
conducted using treatment probabilities derived from baseline comorbidities, medications, 
and demographic information to achieve balance between treatment groups. A multivariable 
logistic regression model was used to predict the propensity of receiving one treatment 
versus the other for each pair and included all baseline characteristics (Table 1). Patients 
were matched on this propensity score with another patient with the same type of cancer in 
the comparison treatment group using a greedy algorithm (“gmatch” SAS macro) allowing 
for up to 4 matches. Matches were required to have a propensity score within 20% of the 
standard deviation of the cohort’s mean propensity score. Once matched, pairs are 
theoretically similar, conditional on the included covariates in the logistic regression model 
generating the propensity score estimates [34]. Standardized differences were calculated to 
assess the balance achieved between the treatment groups by the matching process [35]. 
Standardized differences of <0.10 are generally considered to be non-significant. Covariates 
with standardized differences above this threshold were also incorporated in the final 
regression models to reduce any residual selection bias. Comparison of the pre-matched 
sample (Appendix Table 1) using standard p-values was not done due to the use of the 
matched sample for study results. Incidence rates were calculated based on cumulative 
follow-up per 1000 person-years and the number needed to treat (NNT) was calculated 
based on the differences between incidence rates for the comparison groups.
2.6. Survival analysis
The study cohort was followed until subjects died, were lost to follow-up, or the end of the 
study data (December 31, 2013). Since the competing risk of death was present in the cohort 
and would prevent the occurrence of the outcomes of interest, two survival regression 
models were estimated – a cause-specific hazard model and a sub-distribution hazard model 
[36]. These models differ in how patients who die during follow-up are included in the risk 
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set. In the cause-specific model, death is treated as a censoring event; thus, it reduces to a 
traditional Cox proportional hazard model. The resulting cause-specific hazard ratio (csHR) 
represents the instantaneous rate of VTE among subjects who are event free (no VTE, no 
death) [36]. The sub-distribution model retains those who die in the risk set at each time 
interval and the sub-distribution HRs represent the instantaneous rate of VTE in those who 
have not experienced VTE or who have died. Including both models allowed for a more 
broad interpretation of results as each has unique implications and applications [36]. This 
manuscript primarily reports results from the cause-specific models as they are more 
traditionally interpreted similarly to Cox proportional hazard models. Results from the sub-
distribution models are presented in Appendix Table 2 for the primary analyses only. Models 
for separate DVT and PE outcomes were estimated overall as well as stratified by each 
cancer type. Time-varying treatment models were considered, however, it was observed that 
the overall statin and non-statin utilization was ≥90% during follow-up, making a time-
varying treatment model unlikely to influence results. The cumulative incidence of a 
composite DVT/PE outcome was also estimated accounting for death as a competing risk 
using the Fine and Gray method. The assumption of proportional hazards was checked and 
confirmed using Schoenfeld residuals. Hazard ratios and cumulative incidence estimates are 
presented with 95% confidence intervals in parentheses. Data management and statistical 
analyses were conducted using SAS Enterprise Guide version 7.1 (Cary, NC).
2.7. Sensitivity analyses
A sensitivity analysis assessing the influence of age as an effect modifier stratified the 
overall survival models by ages ≤64, 65–74, and 75 and older as these patients may have 
different treatments patterns, response, and varying baseline survival. Statins were also 
internally compared as individual chemical entities and by type (natural vs. synthetic) to 
ascertain if differences among statins influence outcomes. Natural statins include lovastatin, 
pravastatin and simvastatin and synthetic statins included rosuvastatin, atorvastatin, 
fluvastatin and pitavastatin. Influence of a statin dose-response relationship was also 
explored but did not differ from the primary analyses.
3. Results
During the 5-year study period, 170,459 patients with cancer met the eligibility criteria with 
lung, lymphomas, and colorectal cancers being the most commonly diagnosed cancers. The 
three treatment groups included statins (N = 61,057), non-statins (N = 10,268), and no 
treatment (N = 99,134). At baseline, these three groups differed by age and comorbid 
conditions; however, propensity score matching provided matched pairs that were similar 
based on standardized differences (Table 1). Each treatment group contributed an average of 
290 days of follow-up per patient with non-significant differences (±5 days) in follow-up 
time.
3.1. Statins vs. no treatment
After propensity score matching, 39,821 statin users matched 1:1 with the no treatment 
group. The incidence rate (Table 2) between the statin and no treatment groups was 72.7 
versus 80.1 DVTs (NNT = 146, P < 0.001) and 33.4 versus 35.6 PEs (NNT = 471, P > 0.05) 
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per 1000 person-years. The one-year cumulative incidence of DVT/PE combined was 8.1% 
(7.9%–8.4%) and 8.3% (8.2%–8.5%) in the statin and untreated groups. In the cause-specific 
survival model (Table 3), statin treatment was associated with a small reduction in DVT 
[csHR 0.92 (0.87–0.97)]. In analyses stratified by cancer type, leukemia and colorectal 
cancers accounted for the only significant results. For leukemia, there was a reduction in 
DVT only [csHR 0.77 (0.61–0.99)]. Point estimates for PE outcomes in the leukemia were 
all <1.0, but included wide confidence intervals, which included the null. In colorectal 
cancer, the risk of PE [csHR 0.80 (0.64–0.99)] was significantly reduced. Results from the 
sub-distribution hazard models were similar in direction and magnitude for these and all 
further results (Appendix Table 2). Similarly, results using the more broad definition of VTE 
provided nearly identical results to the more strict event coding (Appendix Table 3).
3.2. Statins vs. non-statins
In the comparison between statin and non-statin cholesterol-lowering medications, the 
overall model showed no significant results in a matched sample of 51,983 statin users and 
15,334 non-statin users. The incidence rate in each group was 72 versus 71.2 DVTs (NNT > 
1000) and 33.3 versus 34.5 PEs (NNT = 862) per 1000 person-years (both P > 0.05), 
respectively. The cumulative incidence of DVT/PE at 1-year of follow-up was 8.2% (7.9%–
8.5%) for the statin group and 8.5% (7.9%–9.1%) in the non-statin group. When stratified by 
cancer type, only lung cancer showed a protective effective of statins for PE [csHR 0.79 
(0.64–0.99)] but not for DVT.
3.3. Non-statins vs. no treatment
There was significant differences in DVT incidence between non-statin (N = 10,621) and no 
treatment (N = 37,098) groups (71.5 vs. 79, NNT = 144, P < 0.001) in the observed 
incidence of DVT but not PE (34.6 vs. 35.2, NNT > 1000, P > 0.05). The cumulative 
incidence of any VTE at 1-year was comparable at 8.5% (7.9%–9.1%) in the non-statin 
group and 8.5% (8.1%–8.8%) in the untreated group. In all models comparing the non-statin 
and untreated groups, there were no significant findings for either outcome.
3.4. Statin sensitivity analysis
Among the statin treated group, 37,318 (61.1%) received natural statins including 
simvastatin (N = 26,818; 71.9% of natural statin users) pravastatin (N = 6824; 18.3%), and 
lovastatin (N = 3676; 9.9%). Synthetic statins were used by 23,739 (38.9%) of patients and 
included atorvastatin (N = 17,224; 72.6% of synthetic statin users), rosuvastatin (N = 6063; 
25.5%), fluvastatin (N = 347; 1.5%), and pitavastatin (N = 105, 0.4%). When comparing 
natural versus synthetic statins, there was no difference in outcomes (Table 4). A more in-
depth analysis using simvastatin as the reference group, found no significant differences 
observed between any of the individual statins versus simvastatin in DVT or PE outcomes 
(Table 4).
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3.5. Age stratification sensitivity analysis
When the overall model was stratified by age groups, the protective effect on DVT observed 
for statins and non-statin treated patients compared to untreated patients was present only for 
those 75 and older (Table 5).
4. Discussion
Statins have been an attractive target in the literature for prevention of VTE given the 
general safety of the class, effectiveness in reducing cardiovascular disease, and broader 
pleiotropic, and potential anti-cancer activity. In the cancer population, having new options 
for adjunct treatment for primary or secondary prevention of VTE is desirable given the 
considerable burden of VTE associated with cancer, high risk of recurrence, and difficulty in 
managing anticoagulation in these patients [38].
The current study utilized pharmacoepidemiological techniques to compare the treatment 
effect of statins on the rate of DVT and PE in a cancer cohort compared to non-statin, 
cholesterol-lowering medications and an untreated group. Compared to the no treatment 
group, statins had a small protective effect (10–15%) in VTE associated with colorectal 
cancer and leukemias. These results did not hold true for other cancer types or for in 
comparisons of statins to non-statin medications. The estimated number needed to treat 
(NNT) compared for statins compared to no treatments is >100 and may not meet an 
acceptable threshold to initiate new pharmacotherapy for newly diagnoses cancers to prevent 
VTE. Further, there were no protective results shown with statins for PE in any of the 
models other than for the comparison of statins versus non-statins for lung cancer (HR = 
0.79, 95% CI 0.64–0.99). Stratification by age showed that these results were only consistent 
in patients ≥75 years old – a finding that deserves further investigation. Therefore, there 
seems to not be an overall protective benefit from using statins when compared either to 
non-statin cholesterol-lowering drugs or no treatment. It is unknown whether there may be a 
pathway by which statins may show a differential protective effect only for DVTs and only 
in colorectal cancer and leukemias. The few protective findings we did observe may have 
been spurious or need further study to identify physiological or pharmacological pathways 
to explain these effects.
These results differ from those observed in other clinical trials and observational studies in 
the general population without concurrent cancer. The JUPITER trial, which randomized 
patients with low-density lipoprotein cholesterol levels <130 mg/dL and C-reactive protein 
levels ≥2.0 mg/L to receive rosuvastatin or placebo, found a 40–50% reduction in the rate of 
VTE [17]. The strict selection criteria of the JUPITER trial may confound the comparison 
and generalizability of those findings to the general population. Similarly, a study by Lassila 
and colleagues found a reduction in VTE of 40% but with a wide confidence interval that 
approached the null [18]. Meta-analyses have also shown a smaller (10–20%) marginal 
effect of statins in the general population, which is more consistent to the findings in our 
study focusing on a cancer population [15,19].
Two known studies have specifically investigated statin use and VTE risk in cancer. Lötsch 
et al. used propensity score weighting techniques to compare statin users with non-users in 
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newly diagnosed cancer or cancer in remission [23]. They observed a protective effect of 
statins using a sub-distribution hazard model (sdHR = 0.43, 95% CI 0.19–0.98) and 
investigated the effect of multiple biomarkers for VTE risk. However, this study was limited 
by a relatively small sample (N = 1434) and, in particular, with only 6 VTE events in the 
statin group [23]. Further, comparison to a no treatment group can be troublesome given lack 
of indication for the therapy of interest – in this case statins, and no assessment of how the 
no treatment group compared to the statin user group was included in that study. In addition 
to statin users and non-users being confounded by indication, healthy user bias is also 
possible between statin users and no treatment groups wherein individuals who should be on 
statins are not due to non-compliance to treatment or due to other factors. To address this, 
our study used both an active comparator with similar therapeutic indications (non-statin 
cholesterol-lowering medications) in addition to restricting the no treatment comparator to 
those with statin indications. Including an active comparator helps to control for this effect 
and provides a more comparable group to the statin users. Another study used a case-control 
study design of 740 patients at a single medical center. Their results suggested a protective 
association with statin use, however, they were similarly limited in the number of events (N 
= 16) in the statin user group as well as the general limitations of case-control studies [20].
Despite the lack of a large observed effect in this study, statins have potential for other 
repurposed use in cancer. A recent study compared the use of aspirin, statins, selective 
serotonin reuptake inhibitors, adrenergic receptor alpha 1 antagonist, and tricyclic 
antidepressants in small cell lung cancer identified a statistically significant increase in 
median overall survival associated with statin treatment (8.4 vs. 6 months, respectively; P = 
0.002) [39]. This effect may be due to statins’ influence on the mevalonate pathway, of 
which, HMG\\CoA reductase is the rate-limiting enzyme. In turn, this will lead to decreased 
production of downstream mevalonate derivatives, farnesyl pyrophosphate (FPP), and 
geranyl geranyl pyrophosphate (GGPP) [40]. Ras activation requires covalent attachment to 
FPP or GGPP to be directed to the endoplasmic reticulum for further processing [41]. Ras 
protein activation leads to transcription of several different genes involved in cell 
differentiation [42]. Thus, despite our results for VTE, investigation into the effect of statins 
in cancer should continue in order to elucidate pathways by which statins may exert 
unintended benefits of their use [19].
4.1. Limitations
This study is subject to the limitations of all claims-based studies [43, 44]. Notably, claims 
data lack detailed information on laboratory values, additional sociodemographic 
information, smoking status, or information on tumor staging, which may have influenced 
the outcomes of this study but is not expected to be differential between comparison groups. 
The population included in the claims database included individuals covered by employer 
provided, commercial or retiree health insurance and is generalizable to the commercially 
insured population in the U.S. but may not be generalizable to other populations. This study 
was limited to a one-year follow-up due to the availability of data and the potential for time-
varying confounded and increased heterogeneity with longer follow-up of patients with 
cancer. Analyses were stratified by cancer type to investigate effects within each cancer but 
also to control for varying baseline hazards as well as varying treatment trajectories between 
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cancers. While treatments including chemotherapy, radiation, surgery, use of 
thromboprophylaxis, etc. may differ between cancers and are known to be associated with 
VTE risk, it is not expected to be differential between treatment groups within the same 
cancer type. Studies with longer follow-up are needed to confirm the sustainability of the 
protective effect of statins observed in this study and detailed investigation incorporating 
time-varying cancer treatment characteristics within each cancer may be warranted for those 
cancers (renal, colorectal, and leukemias) where a protective signal was observed. Lastly, 
while propensity score matching is known to reduce selection bias in non-randomized 
studies, it is possible that residual bias is present, especially when there are important 
unmeasured confounders that are not included in the model [33]. This study is strengthened 
by a large sample size, a large number of outcome events, inclusion of minimum medication 
exposure criteria (i.e. 90 days supplied in pre-index period), and by inclusion of an active 
control group in addition to tight restriction of the no treatment comparator group, which 
have all been lacking in previous studies.
5. Conclusion
In this propensity score matched sample of patients with cancer, statins were shown to have 
a small protective effect in colorectal cancers and leukemias for the risk of DVT. The lack of 
effect was consistent across sensitivity analyses included and did not persist in comparisons 
to non-statin medications. While this study indicates statins may not have a role in 
preventing cancer-associated VTE, there exist other opportunities for statins to be 
repurposed in other therapeutic applications.
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Appendix A
Appendix Table 1
Cohort characteristics prior to propensity score matching.
Treatment group
Statins
N = 61,057
Non-statins
N = 10,268
No treatment
N = 99,134
Mean SD Mean SD Mean SD
Age 74.8 7.9 72.3 9.1 62.9 12.1
Charlson comorbidity index 5.1 3.0 5.1 3.0 4.9 3.1
N % N % N %
Gender (Male) 32,101 52.6% 5587 54.4% 47,030 47.4%
Urban residence 51,917 85.0% 8584 83.6% 82,791 83.5%
Comorbidities assessed during pre-index
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Treatment group
Statins
N = 61,057
Non-statins
N = 10,268
No treatment
N = 99,134
Mean SD Mean SD Mean SD
Heart failure 9609 15.7% 1413 13.8% 9609 9.7%
Arrhythmias 17,517 28.7% 2605 25.4% 20,640 20.8%
Valvular disease 9942 16.3% 1503 14.6% 11,794 11.9%
Pulmonary circulation 2487 4.1% 394 3.8% 3500 3.5%
Peripheral vascular 18,620 30.5% 2859 27.8% 18,735 18.9%
Hypertension uncomplicated 42,825 70.1% 7154 69.7% 63,465 64.0%
Hypertension complicated 6717 11.0% 1139 11.1% 8463 8.5%
Paralysis 653 1.1% 98 1.0% 1123 1.1%
Other neurological 4871 8.0% 752 7.3% 7784 7.9%
Chronic pulmonary 18,532 30.4% 2925 28.5% 25,471 25.7%
Diabetes 20,275 33.2% 3926 38.2% 39,227 39.6%
Diabetes with end organ damage 7017 11.5% 1347 13.1% 9865 10.0%
Hypothyroidism 8468 13.9% 1537 15.0% 17,127 17.3%
Renal failure 7958 13.0% 1551 15.1% 9246 9.3%
Liver disease 5132 8.4% 1009 9.8% 12,984 13.1%
Peptic ulcer disease 1177 1.9% 198 1.9% 2048 2.1%
HIV/AIDS 44 0.1% 26 0.3% 449 0.5%
Lymphoma 11,943 19.6% 2178 21.2% 20,612 20.8%
Metastatic cancer 9204 15.1% 1455 14.2% 17,792 17.9%
Solid tumors 47,821 78.3% 7837 76.3% 76,316 77.0%
Rheumatoid arthritis 2972 4.9% 555 5.4% 5422 5.5%
Coagulopathy 3414 5.6% 555 5.4% 6318 6.4%
Obesity 3161 5.2% 697 6.8% 10,027 10.1%
Weight loss 4652 7.6% 716 7.0% 8122 8.2%
Fluids and electrolytes 8509 13.9% 1348 13.1% 15,904 16.0%
Blood loss anemia 3710 6.1% 540 5.3% 5498 5.5%
Deficiency anemia 4884 8.0% 839 8.2% 8283 8.4%
Alcohol abuse 487 0.8% 72 0.7% 1596 1.6%
Drug abuse 323 0.5% 50 0.5% 1080 1.1%
Psychoses 1146 1.9% 179 1.7% 1922 1.9%
Depression 4745 7.8% 806 7.8% 12,542 12.7%
Coronary heart disease 22,128 36.2% 3601 35.1% 24,350 24.6%
Myocardial infarction 4281 7.0% 626 6.1% 4912 5.0%
Hyperlipidemia 37,525 61.5% 6165 60.0% 72,310 72.9%
Medication use in pre-index
Anticoagulants 7995 13.1% 1144 11.1% 5294 5.3%
Antihypertensives 44,666 73.2% 6971 67.9% 31,281 31.6%
Antiplatelets 1013 1.7% 1510 14.7% 3544 3.6%
Antiarrhythmics 2275 3.7% 321 3.1% 1306 1.3%
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Treatment group
Statins
N = 61,057
Non-statins
N = 10,268
No treatment
N = 99,134
Mean SD Mean SD Mean SD
Digoxin 2960 4.8% 470 4.6% 1908 1.9%
Cancer type
Stomach 1715 2.8% 267 2.6% 2904 2.9%
Pancreas 2786 4.6% 498 4.9% 5295 5.3%
Brain 1582 2.6% 283 2.8% 4135 4.2%
Lung 14,734 24.1% 2262 22.0% 17,076 17.2%
Kidney 5881 9.6% 1092 10.6% 10,399 10.5%
Lymphoma 9257 15.2% 1670 16.3% 16,283 16.4%
Leukemia 5704 9.3% 1056 10.3% 8803 8.9%
Myeloma 2801 4.6% 535 5.2% 4626 4.7%
Colorectal 12,285 20.1% 1964 19.1% 19,660 19.8%
Gynecologic 5517 8.8% 729 8.2% 32,303 15.0%
Appendix Table 2
Sub-distribution hazard ratios of venous thromboembolism outcomes in pairwise propensity 
score matched regression.
Outcome*
Statins vs. non-statins Statins vs. no treatment
Non-statins vs. no 
treatment
sdHR 95% CI sdHR 95% CI sdHR 95% CI
All cancers DVT (general) 0.96 0.88 1.05 0.93 0.89 0.97 1.02 0.93 1.12
PE (general) 0.91 0.79 1.05 0.95 0.88 1.01 1.00 0.87 1.16
DVT (specific) 0.98 0.89 1.08 0.93 0.89 0.97 1.01 0.91 1.11
PE (specific) 0.92 0.80 1.06 0.95 0.89 1.02 1.01 0.87 1.16
Stomach DVT (general) 1.40 0.93 2.09 0.91 0.76 1.10 0.82 0.53 1.25
PE (general) 1.17 0.67 2.05 0.94 0.73 1.20 1.01 0.55 1.84
DVT (specific) 1.41 0.91 2.20 0.89 0.74 1.08 0.76 0.48 1.19
PE (specific) 1.17 0.67 2.05 0.94 0.73 1.20 1.01 0.55 1.84
Pancreas DVT (general) 0.92 0.68 1.25 1.09 0.94 1.26 1.28 0.94 1.75
PE (general) 1.22 0.70 2.11 1.00 0.80 1.26 0.80 0.46 1.37
DVT (specific) 0.90 0.67 1.22 1.12 0.97 1.30 1.32 0.96 1.81
PE (specific) 1.22 0.70 2.11 1.02 0.81 1.28 0.81 0.47 1.39
Brain DVT (general) 1.03 0.65 1.66 1.18 0.95 1.46 1.05 0.62 1.77
PE (general) 0.78 0.40 1.53 1.21 0.86 1.70 1.12 0.51 2.49
DVT (specific) 1.05 0.64 1.72 1.17 0.94 1.46 1.06 0.62 1.83
PE (specific) 0.78 0.40 1.53 1.21 0.86 1.70 1.12 0.51 2.49
Lung DVT (general) 0.93 0.77 1.12 0.95 0.86 1.03 1.08 0.89 1.32
PE (general) 0.82 0.65 1.05 0.91 0.81 1.03 1.06 0.82 1.35
DVT (specific) 0.97 0.79 1.19 0.94 0.85 1.03 1.07 0.87 1.32
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Outcome*
Statins vs. non-statins Statins vs. no treatment
Non-statins vs. no 
treatment
sdHR 95% CI sdHR 95% CI sdHR 95% CI
PE (specific) 0.82 0.64 1.04 0.91 0.81 1.03 1.07 0.83 1.37
Renal DVT (general) 1.19 0.82 1.74 0.89 0.75 1.06 0.86 0.59 1.25
PE (general) 1.02 0.54 1.93 0.86 0.64 1.15 1.10 0.60 2.00
DVT (specific) 1.12 0.77 1.63 0.90 0.75 1.07 0.99 0.67 1.46
PE (specific) 1.02 0.54 1.93 0.86 0.64 1.15 1.10 0.60 2.00
Lymphoma DVT (general) 0.77 0.60 1.00 0.91 0.80 1.04 1.23 0.94 1.62
PE (general) 0.78 0.51 1.19 1.02 0.81 1.27 1.50 0.94 2.41
DVT (specific) 0.75 0.57 0.99 0.90 0.79 1.03 1.24 0.93 1.65
PE (specific) 0.78 0.51 1.19 1.02 0.82 1.27 1.50 0.94 2.41
Leukemia DVT (general) 0.91 0.62 1.33 0.83 0.69 0.99 1.04 0.71 1.51
PE (general) 0.78 0.41 1.48 0.77 0.54 1.09 1.38 0.74 2.57
DVT (specific) 1.03 0.67 1.58 0.78 0.64 0.95 0.83 0.55 1.26
PE (specific) 0.84 0.43 1.64 0.80 0.56 1.14 1.33 0.72 2.47
Myeloma DVT (general) 1.33 0.84 2.09 0.86 0.71 1.04 0.80 0.51 1.25
PE (general) 2.85 0.89 9.18 0.95 0.67 1.33 0.38 0.13 1.14
DVT (specific) 1.38 0.84 2.28 0.89 0.73 1.08 0.79 0.49 1.26
PE (specific) 2.85 0.89 9.18 0.94 0.67 1.33 0.41 0.13 1.24
Colorectal DVT (general) 0.88 0.71 1.09 0.84 0.76 0.93 0.92 0.73 1.15
PE (general) 0.89 0.60 1.31 0.83 0.69 0.99 0.74 0.50 1.09
DVT (specific) 0.95 0.75 1.19 0.88 0.79 0.97 0.91 0.71 1.15
PE (specific) 0.92 0.62 1.37 0.83 0.69 1.00 0.71 0.48 1.06
Gynecologic DVT (general) 1.11 0.78 1.58 0.97 0.84 1.11 1.00 0.69 1.45
PE (general) 0.94 0.54 1.62 1.11 0.89 1.38 1.31 0.69 2.49
DVT (specific) 1.14 0.79 1.67 0.96 0.82 1.11 0.94 0.63 1.40
PE (specific) 0.94 0.54 1.62 1.12 0.90 1.39 1.37 0.72 2.59
Abbreviations: DVT = deep vein thrombosis; PE = pulmonary embolism.
*
General and specific outcomes refer to the ICD-9 code definition used for each outcome.
Appendix Table 3
Cause-specific hazard ratios of venous thromboembolism using a broad coding definition for 
outcome events.
Statins vs. non-statins Statins vs. no treatment
Non-statins vs. no 
treatment
csHR 95% CI csHR 95% CI csHR 95% CI
All cancers DVT (general) 0.97 0.89 1.06 0.92 0.87 0.98 0.94 0.86 1.02
PE (general) 0.94 0.82 1.07 0.94 0.87 1.03 1.01 0.88 1.16
Stomach DVT (general) 1.30 0.88 1.90 0.88 0.70 1.10 0.72 0.49 1.06
PE (general) 1.20 0.69 2.08 0.98 0.72 1.34 0.65 0.37 1.13
Pancreas DVT (general) 0.80 0.61 1.05 1.04 0.87 1.24 1.31 0.99 1.73
PE (general) 1.10 0.68 1.78 0.89 0.68 1.17 1.20 0.73 1.97
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Statins vs. non-statins Statins vs. no treatment
Non-statins vs. no 
treatment
csHR 95% CI csHR 95% CI csHR 95% CI
Brain DVT (general) 0.95 0.61 1.48 1.04 0.80 1.37 0.89 0.53 1.47
PE (general) 0.83 0.43 1.60 1.11 0.74 1.66 0.97 0.48 1.95
Lung DVT (general) 0.97 0.81 1.16 0.92 0.82 1.03 1.01 0.84 1.21
PE (general) 0.79 0.64 0.99 0.94 0.81 1.10 1.13 0.90 1.43
Renal DVT (general) 1.27 0.88 1.83 0.90 0.73 1.12 0.72 0.50 1.05
PE (general) 1.30 0.68 2.48 0.91 0.63 1.32 0.96 0.52 1.76
Lymphoma DVT (general) 0.86 0.67 1.09 0.88 0.75 1.04 1.03 0.80 1.32
PE (general) 0.76 0.50 1.14 1.07 0.80 1.42 1.42 0.92 2.18
Leukemia DVT (general) 0.91 0.64 1.29 0.85 0.68 1.06 0.95 0.67 1.35
PE (general) 0.74 0.41 1.35 0.89 0.57 1.39 1.03 0.58 1.85
Myeloma DVT (general) 1.23 0.83 1.84 0.99 0.78 1.25 0.82 0.54 1.23
PE (general) 1.91 0.79 4.61 1.07 0.68 1.69 0.66 0.25 1.73
Colorectal DVT (general) 0.92 0.75 1.13 0.87 0.76 0.98 0.87 0.71 1.08
PE (general) 0.98 0.67 1.42 0.80 1.00 1.00 0.86 0.59 1.25
Gynecologic DVT (general) 1.08 0.78 1.49 1.07 0.89 1.30 0.84 0.58 1.21
PE (general) 1.06 0.65 1.72 1.07 0.80 1.44 1.06 0.61 1.83
Abbreviations: csHR = cause-specific hazard ratio; DVT = deep vein thrombosis; PE = pulmonary embolism.
Appendix Table 4
Follow-up time and number of events for treatment cohorts in each matched comparison.
Treatment group N Follow-up time (person-years) Event Number of events % with event Incidence per 
1000 person-
years (95% CI)
Statins vs. non-statins
Statins 51,983 33,469.5 DVT (specific) 2410 4.64% 72 (69.2–74.9)
DVT (general) 2646 5.09% 79.1 (76.1–82.1)
PE (specific) 1113 2.14% 33.3 (31.3–35.3)
PE (general) 1116 2.15% 33.3 (31.4–35.3)
Non-statins 15,334 8240.2 DVT (specific) 587 3.83% 71.2 (65.6–77.2)
DVT (general) 657 4.28% 79.7 (73.8–86.0)
PE (specific) 284 1.85% 34.5 (30.6–38.7)
PE (general) 286 1.87% 34.7 (30.9–38.9)
Statins vs. no treatment
Statins 39,821 31,716.6 DVT (specific) 2306 5.79% 72.7 (69.8–75.7)
DVT (general) 2536 6.37% 80 (76.9–83.1)
PE (specific) 1060 2.66% 33.4 (31.5–35.5)
PE (general) 1063 2.67% 33.5 (31.6–35.6)
No treatment 39,821 31,298.2 DVT (specific) 2507 6.30% 80.1 (77.0–83.3)
DVT (general) 2737 6.87% 87.4 (84.2–90.8)
PE (specific) 1113 2.80% 35.6 (33.5–37.7)
PE (general) 1139 2.86% 36.4 (34.9–36.3)
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Treatment group N Follow-up time (person-years) Event Number of events % with event Incidence per 
1000 person-
years (95% CI)
Non-statins vs. no treatment
Non-statins 10,621 8333.3 DVT (specific) 596 5.61% 71.5 (66.0–77.4)
DVT (general) 668 6.29% 80.2 (74.3–86.4)
PE (specific) 288 2.71% 34.6 (30.7–38.7)
PE (general) 290 2.73% 34.8 (31.0–39.0)
No treatment 37,098 23,390.7 DVT (specific) 1848 4.98% 79 (75.5–82.7)
DVT (general) 2025 5.46% 86.6 (82.9–90.4)
PE (specific) 823 2.22% 35.2 (32.8–37.7)
PE (general) 828 2.23% 35.4 (33.1–37.9)
“General” outcomes refer to a broader coding definition using ICD-9451.xx and 453.xx for DVT and 415.1x for PE. 
“Specific” outcome definitions are based on a more validated subset of codes within these codes.
Abbreviations: deep vein thrombosis (DVT); pulmonary embolism (PE); confidence interval (CI).
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Table 3
Cause-specific hazard ratio of risk for deep vein thrombosis and pulmonary embolism in the overall and 
cancer-stratified regression models in propensity score matched treatment groups.
Deep vein thrombosis Pulmonary embolism
Statins Vs. non-statins All cancers 0.99 (0.91–1.09) 0.94 (0.82–1.07)
Stomach 1.27 (0.84–1.91) 1.18 (0.68–2.05)
Pancreas 0.80 (0.60–1.06) 1.10 (0.68–1.78)
Brain 0.93 (0.59–1.47) 0.83 (0.43–1.60)
Lung 1.01 (0.84–1.22) 0.79 (0.64–0.99)*
Renal 1.16 (0.81–1.68) 1.30 (0.68–2.48)
Lymphoma 0.86 (0.66–1.12) 0.76 (0.50–1.14)
Leukemias 1.02 (0.69–1.51) 0.81 (0.44–1.49)
Myeloma 1.25 (0.81–1.94) 1.91 (0.79–4.61)
Colorectal 0.97 (0.78–1.20) 1.01 (0.69–1.48)
Gynecological 1.10 (0.78–1.55) 1.06 (0.65–1.72)
Statins Vs. no treatment All cancers 0.92 (0.87–0.97)* 0.95 (0.87–1.03)
Stomach 0.81 (0.64–1.03) 0.98 (0.72–1.34)
Pancreas 1.01 (0.84–1.22) 0.91 (0.69–1.19)
Brain 0.97 (0.73–1.27) 1.11 (0.74–1.66)
Lung 0.93 (0.83–1.06) 0.94 (0.81–1.10)
Renal 0.97 (0.77–1.21) 0.91 (0.63–1.32)
Lymphoma 0.88 (0.74–1.04) 1.07 (0.80–1.42)
Leukemias 0.77 (0.61–0.99)* 0.91 (0.58–1.43)
Myeloma 0.98 (0.76–1.25) 1.07 (0.68–1.69)
Colorectal 0.90 (0.79–1.02) 0.80 (0.64–0.99)*
Gynecological 1.02 (0.83–1.25) 1.09 (0.82–1.46)
Non-Statins Vs. no treatment All cancers 0.92 (0.84–1.01) 1.01 (0.88–1.16)
Stomach 0.68 (0.45–1.03) 0.65 (0.37–1.13)
Pancreas 1.33 (1.00–1.77)* 1.24 (0.75–2.03)
Brain 0.81 (0.47–1.40) 0.97 (0.48–1.95)
Lung 1.01 (0.83–1.23) 1.13 (0.90–1.43)
Renal 0.81 (0.56–1.18) 0.96 (0.52–1.76)
Lymphoma 0.97 (0.74–1.27) 1.42 (0.92–2.18)
Leukemias 0.81 (0.55–1.19) 0.99 (0.55–1.78)
Myeloma 0.80 (0.52–1.23) 0.69 (0.26–1.79)
Colorectal 0.84 (0.67–1.05) 0.83 (0.57–1.22)
Gynecological 0.84 (0.57–1.23) 1.06 (0.61–1.83)
*
Indicates statistical significance at p < 0.05.
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Table 4
Cause-specific hazard ratios of venous thromboembolism within the statin-treated group by individual 
products and natural or synthetic statins.
Deep vein thrombosis Statin used Hazard ratio (95% Confidence interval)
Synthetic Reference
Natural 0.96 (0.90–1.03)
Simvastatin Reference
Lovastatin 1.07 (0.93–1.23)
Pravastatin 0.99 (0.89–1.11)
Rosuvastatin 1.02 (0.91–1.15)
Atorvastatin 1.06 (0.98–1.15)
Fluvastatin 1.03 (0.67–1.59)
Pitavastatin 1.10 (0.50–2.41)
Pulmonary embolism Synthetic Reference
Natural 1.01 (0.92–1.12)
Simvastatin Reference
Lovastatin 0.91 (0.73–1.14)
Pravastatin 0.97 (0.82–1.14)
Rosuvastatin 0.91 (0.76–1.09)
Atorvastatin 0.99 (0.88–1.11)
Fluvastatin 0.99 (0.53–1.86)
Pitavastatin 1.78 (0.74–4.26)
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Table 5
Cause-specific hazard ratios of venous thromboembolism within pairwise comparisons of the treatment groups 
stratified by age.
Statins vs. non-statins Statin vs. non-users Non-statins vs. non-users
Age Outcome Hazard ratio (95% Confidence 
interval)
Hazard ratio (95% Confidence 
interval)
Hazard ratio (95% Confidence interval)
≤65 years DVT 0.95 (0.71–1.29) 1.07 (0.87–1.31) 1.25 (0.98–1.59)
PE 0.69 (0.44–1.07) 0.98 (0.71–1.36) 1.17 (0.85–1.71)
65–74 years DVT 0.93 (0.81–1.06) 0.93 (0.86–1.02) 1.03 (0.89–1.18)
PE 0.90 (0.75–1.08) 0.93 (0.82–1.05) 1.04 (0.85–1.27)
≥75 years DVT 1.15 (0.98–1.34) 0.87 (0.80–0.96) 0.82 (0.70–0.97)
PE 1.09 (0.87–1.36) 0.92 (0.80–1.05) 0.93 (0.73–1.18)
Abbreviations: deep vein thrombosis (DVT); pulmonary embolism (PE).
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